丹红注射液对冠心病介入治疗后血瘀证患者不良心血管事件的影响

Effect of Danhong Injection on Adverse Cardiovascular Events in Patients with Blood Stasis Syndrome after Interventional Therapy for Coronary Heart Disease

目的探讨丹红注射液对冠心病介入治疗后血瘀证患者不良心血管事件的影响。方法选取该院2015年1月-2017年1月收治的80例PCI术后患者为研究对象,根据不同治疗方法将本组患者随机分为两组,观察组(n=40)给予丹红注射液治疗,对照组(n=40)给予常规西医治疗,对比两组患者MACE发生情况和炎症因子水平、血管内皮功能以及血栓形成指标。结果观察组患者MACE发生率20.00%明显低于对照组35.00%,差异有统计学意义(χ^2=11.7818,P<0.05)。观察组患者ICAM-1、IL-6、TNF-α、hs-CRP、Hcy、vWF、ET-1分别为(88.83±18.25)ng/L、(18.13±2.33)μg/L、(19.88±4.29)μg/L、(9.47±1.63)mg/L、(9.70±1.24)μmol/L、(139.78±11.41)%、(65.36±8.26)ng/L、,明显低于对照组(114.57±20.74)ng/L、(31.24±2.74)μg/L、(23.40±3.23)μg/L、(13.75±1.65)mg/L、(12.58±1.31)μmol/L、(163.95±12.50)%、(73.49±9.34)ng/L,差异有统计学意义(t=5.8927、23.0528、4.1457、11.6710、10.0980、9.0322、4.1239,P<0.05),NO、FMD分别为(67.93±10.51)μmol/L、(7.51±1.14)%,明显高于对对照组(60.56±8.37)μmol/L、(6.64±0.86)%,差异有统计学意义(t=3.4693、3.8532,P<0.05)。结论丹红注射液可有效降低冠心病PCI术后患者MACE发生率和炎症因子水平,改善血管内皮功能,值得临床推广。

Objective To investigate the effect of Danhong injection on adverse cardiovascular events in patients with blood stasis syndrome after interventional therapy for coronary heart disease. Methods Eighty patients with PCI admitted to our hospital from January 2015 to January 2017 were selected. The patients were randomly divided into two groups according to different treatment methods. The observation group (n=40) was given Danhong injection, and the control group (n=40) was given conventional western medicine. The incidence of MACE, inflammatory factor level, vascular endothelial function and thrombosis index were compared between the two groups. Results The incidence of MACE in the observation group was 20.00%, which was significantly lower than that in the control group (35.00%). The difference was statistically significant (χ^2=11.781 8, P<0.05). The ICAM-1, IL-6, TNF-α, hs-CRP, Hcy, vWF, and ET-1 in the observation group were (88.83±18.25) ng/L,(18.13±2.33)μg/L, respectively (19.88±4.29) mg/L,(9.47±1.63) mg/L,(9.70±1.24)μmol/L,(139.78±11.41)%,(65.36±8.26) ng/L, significantly lower than the control group (114.57±20.74) ng/L,(31.24±2.74)μg/L,(23.40±3.23)μg/L,(13.75±1.65) mg/L,(12.58±1.31)μmol/L,(163.95±12.50)%,(73.49± 9.34) ng/L, the difference was statistically significant (t=5.892 7, 23.052 8, 4.145 7, 11.671 0, 10.098 0, 9.032 2, 4.123 9, P<0.05), NO and FMD were (67.93±10.51) mmol/L,(7.51±1.14)%, significantly higher than the control group (60.56±8.37)μmol/L,(6.64±0.86)%, the difference was statistically significant (t=3.469 3, 3.853 2, P<0.05 ). Conclusion Danhong injection can effectively reduce the incidence of MACE and inflammatory factors in patients with coronary heart disease after PCI, and improve vascular endothelial function, which is worthy of clinical promotion.